Tags

Type your tag names separated by a space and hit enter

[Antileukotrienes in the therapy of bronchial asthma].
Recenti Prog Med. 2003 Nov; 94(11):509-15.RP

Abstract

Cysteinyl-leukotrienes (Cys-LTs) are mediators released in bronchial asthma and are both direct bronchoconstriction and proinflammatory substances that mediated several steps in the pathophysiology of chronic asthma, including inflammatory cells recruitment, vascular leakage, and possibly airway remodelling. Available evidence from clinical trials and real-word experience derived from managing patients with asthma justifies a broader role for antileukotriene drugs (anti-LTs) in asthma management than that recommended in the National Asthma Education and Prevention Program and National Institute of Health treatment guidelines. Anti-LTs seem to be effective alternatives to inhaled corticosteroids (ICS) either as monotherapy or as adjunctive therapy that reduces the need for higher doses of ICS in patients with mild-to-moderate persistent asthma. This class of drugs may be used as adjunctive therapy for all levels of disease severity because they are effective in combination with ICS during long-term maintenance therapy. The anti-LTs seem especially effective in preventing aspirin-induced asthma providing an additional advantage of reducing nasal congestion in patients with both asthma and rhinitis and in the treatment of exercise induced-asthma. This class of drugs have several features that are likely to promote adherence to treatment and are generally well tolerated. The available clinical data suggest that anti-LTs should be considered as a therapeutic option or as additive therapy in patients with mild to severe asthma.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Editorial
English Abstract

Language

ita

PubMed ID

14679921

Citation

Riccioni, Graziano, et al. "[Antileukotrienes in the Therapy of Bronchial Asthma]." Recenti Progressi in Medicina, vol. 94, no. 11, 2003, pp. 509-15.
Riccioni G, Della Vecchia R, Menna V, et al. [Antileukotrienes in the therapy of bronchial asthma]. Recenti Prog Med. 2003;94(11):509-15.
Riccioni, G., Della Vecchia, R., Menna, V., Lambo, M. S., Di Ilio, C., & D'Orazio, N. (2003). [Antileukotrienes in the therapy of bronchial asthma]. Recenti Progressi in Medicina, 94(11), 509-15.
Riccioni G, et al. [Antileukotrienes in the Therapy of Bronchial Asthma]. Recenti Prog Med. 2003;94(11):509-15. PubMed PMID: 14679921.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Antileukotrienes in the therapy of bronchial asthma]. AU - Riccioni,Graziano, AU - Della Vecchia,Rosanna, AU - Menna,Vincenzo, AU - Lambo,Massimo Savino, AU - Di Ilio,Carmine, AU - D'Orazio,Nicolantonio, PY - 2003/12/19/pubmed PY - 2004/3/3/medline PY - 2003/12/19/entrez SP - 509 EP - 15 JF - Recenti progressi in medicina JO - Recenti Prog Med VL - 94 IS - 11 N2 - Cysteinyl-leukotrienes (Cys-LTs) are mediators released in bronchial asthma and are both direct bronchoconstriction and proinflammatory substances that mediated several steps in the pathophysiology of chronic asthma, including inflammatory cells recruitment, vascular leakage, and possibly airway remodelling. Available evidence from clinical trials and real-word experience derived from managing patients with asthma justifies a broader role for antileukotriene drugs (anti-LTs) in asthma management than that recommended in the National Asthma Education and Prevention Program and National Institute of Health treatment guidelines. Anti-LTs seem to be effective alternatives to inhaled corticosteroids (ICS) either as monotherapy or as adjunctive therapy that reduces the need for higher doses of ICS in patients with mild-to-moderate persistent asthma. This class of drugs may be used as adjunctive therapy for all levels of disease severity because they are effective in combination with ICS during long-term maintenance therapy. The anti-LTs seem especially effective in preventing aspirin-induced asthma providing an additional advantage of reducing nasal congestion in patients with both asthma and rhinitis and in the treatment of exercise induced-asthma. This class of drugs have several features that are likely to promote adherence to treatment and are generally well tolerated. The available clinical data suggest that anti-LTs should be considered as a therapeutic option or as additive therapy in patients with mild to severe asthma. SN - 0034-1193 UR - https://www.unboundmedicine.com/medline/citation/14679921/[Antileukotrienes_in_the_therapy_of_bronchial_asthma]_ L2 - https://www.diseaseinfosearch.org/result/633 DB - PRIME DP - Unbound Medicine ER -